These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 17078784)

  • 21. Medications do not necessarily normalize cognition in ADHD patients.
    Gualtieri CT; Johnson LG
    J Atten Disord; 2008 Jan; 11(4):459-69. PubMed ID: 17934180
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of reboxetine in the treatment of attention-deficit/hyperactivity disorder in boys with intolerance to methylphenidate: an open-label, 8-week, methylphenidate-controlled trial.
    Cohen-Yavin I; Yoran-Hegesh R; Strous RD; Kotler M; Weizman A; Spivak B
    Clin Neuropharmacol; 2009; 32(4):179-82. PubMed ID: 19644227
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Towards an understanding of the molecular mechanisms underlying the pharmacological treatments of attention deficit hyperactivity disorder].
    Castellanos FX; Acosta MT
    Rev Neurol; 2011 Mar; 52 Suppl 1():S155-60. PubMed ID: 21365598
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder.
    Wilens TE
    J Clin Psychopharmacol; 2008 Jun; 28(3 Suppl 2):S46-53. PubMed ID: 18480677
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
    Chavez B; Sopko MA; Ehret MJ; Paulino RE; Goldberg KR; Angstadt K; Bogart GT
    Ann Pharmacother; 2009 Jun; 43(6):1084-95. PubMed ID: 19470858
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Without treatment the crash threatens].
    Einecke U
    MMW Fortschr Med; 2009 Jan; 151(5):14-6. PubMed ID: 19391404
    [No Abstract]   [Full Text] [Related]  

  • 27. Effects of atomoxetine and methylphenidate on attention and impulsivity in the 5-choice serial reaction time test.
    Navarra R; Graf R; Huang Y; Logue S; Comery T; Hughes Z; Day M
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jan; 32(1):34-41. PubMed ID: 17714843
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current strategies in the diagnosis and treatment of childhood attention-deficit/hyperactivity disorder.
    Rader R; McCauley L; Callen EC
    Am Fam Physician; 2009 Apr; 79(8):657-65. PubMed ID: 19405409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [ADHD in adults].
    Thomsen PH; Damm D
    Ugeskr Laeger; 2008 Oct; 170(43):3395-9. PubMed ID: 18976592
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Medication options when treating children and adolescents with ADHD: interpreting the NICE guidance 2006.
    Harpin VA
    Arch Dis Child Educ Pract Ed; 2008 Apr; 93(2):58-65. PubMed ID: 18356307
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improving decision making in the treatment of ADHD.
    Vitiello B
    Am J Psychiatry; 2008 Jun; 165(6):666-7. PubMed ID: 18519529
    [No Abstract]   [Full Text] [Related]  

  • 32. Misinterpreting emotional expressions in attention-deficit/hyperactivity disorder: evidence for a neural marker and stimulant effects.
    Williams LM; Hermens DF; Palmer D; Kohn M; Clarke S; Keage H; Clark CR; Gordon E
    Biol Psychiatry; 2008 May; 63(10):917-26. PubMed ID: 18272140
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder.
    Polanczyk G; Zeni C; Genro JP; Guimarães AP; Roman T; Hutz MH; Rohde LA
    Arch Gen Psychiatry; 2007 Feb; 64(2):218-24. PubMed ID: 17283289
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medications for adolescents with attention-deficit/hyperactivity disorder.
    Soileau EJ
    Adolesc Med State Art Rev; 2008 Aug; 19(2):254-67, viii-ix. PubMed ID: 18822831
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Attention deficit and impulsivity: selecting, shifting, and stopping.
    Kenemans JL; Bekker EM; Lijffijt M; Overtoom CC; Jonkman LM; Verbaten MN
    Int J Psychophysiol; 2005 Oct; 58(1):59-70. PubMed ID: 15950304
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response.
    Newcorn JH; Kratochvil CJ; Allen AJ; Casat CD; Ruff DD; Moore RJ; Michelson D;
    Am J Psychiatry; 2008 Jun; 165(6):721-30. PubMed ID: 18281409
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pharmacological treatment of attention-deficit/hyperactivity disorder in adults].
    Rollini M; Baud P
    Rev Med Suisse; 2008 Jul; 4(165):1638-43. PubMed ID: 18767289
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Catecholamine modulators: lessons from nonhuman primates.
    Castellanos FX; Kelly C
    J Am Acad Child Adolesc Psychiatry; 2010 Oct; 49(10):977-9. PubMed ID: 20855042
    [No Abstract]   [Full Text] [Related]  

  • 39. Event-related potentials reflect the efficacy of pharmaceutical treatments in children and adolescents with attention deficit/hyperactivity disorder.
    Yamamuro K; Ota T; Iida J; Nakanishi Y; Matsuura H; Uratani M; Okazaki K; Kishimoto N; Tanaka S; Kishimoto T
    Psychiatry Res; 2016 Aug; 242():288-294. PubMed ID: 27318633
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of pharmacotherapy and managed care pharmacy interventions in the treatment of ADHD.
    Dopheide JA
    Am J Manag Care; 2009 May; 15(5 Suppl):S141-50. PubMed ID: 19601689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.